{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'treatment with a CPI and the limited activity observed with second line chemotherapy', 'underscores the need for more treatment options in this patient population.', 'The potential risks associated with EV are outlined in [Sections 1.2.3', '1.2.4', 'and', '1.3', 'and in', ',', \"the Investigator's Brochure. The potential risks associated with the chemotherapy comparators\", 'are well characterized and are outlined in [Section 5.1 Dosing and Administration of Study', 'Drug(s) and Other Medication(s)], for more detailed information, please refer to their', 'respective local product label.', 'Clinical data to date support a favorable benefit-risk ratio for EV in patients with locally', 'advanced or metastatic urothelial carcinoma who previously received CPI therapy. Evidence', 'of clinical activity has been observed in other single arm studies of EV (described in [Section', '1.2.4 Clinical Data]) and this may translate into an improvement in effectiveness over the', 'control arm. However, there may still be no direct benefit to subjects participating in the', 'current clinical trial. To assure an ongoing favorable risk/benefit assessment for subjects', 'enrolled into the study, an Independent Data Monitoring Committee (IDMC) will be utilized', 'to monitor safety data and interim efficacy analysis.', '2', 'STUDY OBJECTIVE(S), DESIGN AND ENDPOINTS', '2.1', 'Study Objective(s)', '2.1.1', 'Primary Objective', 'To compare the os of subjects with locally advanced or metastatic urothelial cancer treated', 'with EV to the os of patients treated with chemotherapy.', '2.1.2 Secondary Objectives', 'To compare progression free survival on study therapy (PFS1) per Response Evaluation', 'Criteria in Solid Tumors (RECIST) V1.1 of subjects treated with EV to patients treated', 'with chemotherapy', 'To compare the overall response rate (ORR) per RECIST V1.1 of EV to chemotherapy', 'To evaluate the duration of response (DOR) per RECIST V1.1 of EV and chemotherapy', 'To compare the disease control rate (DCR) per RECIST V1.1 of EV to chemotherapy', 'To assess the safety and tolerability of EV', 'To assess quality of life (QOL) and Patient Reported Outcomes (PRO) parameters', '2.1.3 Exploratory Objectives', 'Exploratory genomic and/or other biomarkers in tumor tissue and in peripheral blood that', 'may correlate with treatment outcome, including Nectin-4 expression', 'To assess the pharmacokinetics of EV (TAb, ADC and MMAE)', 'To assess the incidence of ATA', 'To evaluate PFS as assessed by RECIST V1.1 by investigator review in the next line of', 'therapy (PFS2) in subjects treated with EV compared to docetaxel, paclitaxel or vinflunine.', 'Healthcare resources utilization (HRU)', '14 Sep 2020', 'Astellas', 'Page 43 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', '2.2', 'Study Design and Dose Rationale', '2.2.1', 'Study Design', 'This is a global, open-label, randomized Phase 3 study in adult subjects with locally advanced', 'or metastatic urothelial cancer who have received a platinum-containing chemotherapy and', 'have experienced disease progression or relapse during or following treatment with an immune', 'checkpoint inhibitor. Subjects who discontinued CPI treatment due to toxicity are eligible', 'provided that they have evidence of disease progression following discontinuation.', 'Approximately 600 subjects will be randomized to EV (Arm A) or chemotherapy (Arm B) in a', '1:1 ratio. Subjects will be stratified according to the following: Eastern Cooperative Oncology', 'Group Performance Status (ECOG PS), regions of the world and liver metastasis.', 'os is the primary endpoint. OS is defined as the time from randomization to the date of', 'death. Secondary endpoints include PFS1, ORR, DOR, DCR, safety and QOL/PRO.', 'Subjects in Arm A will receive EV on Days 1, 8 and 15 of each 28-day cycle. Subjects in arm', 'B will receive docetaxel, paclitaxel or vinflunine as decided by the investigator prior to', 'randomization, (vinflunine is a choice of comparator only in countries where it is approved', 'for urothelial cancer) on Day 1 of every 21-day cycle. Within the control arm, the overall', 'proportion of subjects receiving vinflunine will be capped at approximately 35%. Subjects', 'will continue to receive study treatment until radiological disease progression as determined', 'per investigator assessment or other discontinuation criteria are met or upon study', 'termination, or study completion, whichever occurs first. No on-study crossover will be', 'allowed other than as allowed in [Appendix 12.10 Subjects assigned to the chemotherapy', 'arm will not be allowed to switch to a different chemotherapy treatment during study', 'treatment. This study will consist of three phases: screening, treatment and follow-up.', 'Screening will take place up to 28 days prior to randomization. Screening assessments may', 'be repeated within the 28-day screening period.', 'Subjects do not need to be \"screen failed\" in IRT and re-entered in screening with a new', 'subject ID as long as the subject is enrolled within the 28-day window from signing of the', 'informed consent. If more than 28 days elapses from the date of signing the informed', 'consent, the subject must be screen failed in IRT. A new consent must be signed and the', 'subject entered into screening with a new subject ID. Subjects may only be rescreened once.', 'Subjects will start with cycle 1 and continue on to subsequent 21-day or 28-day cycles until', 'one of the discontinuation criteria are met or upon study termination, or study completion,', 'whichever occurs first. A treatment cycle is defined as 28 days for Arm A and 21 days for', 'Arm B.', 'Subjects will be evaluated for response according to RECIST V1.1. Imaging for both arms', 'will be performed at baseline and every 56 days ( 7 days) from the first dose of study', 'treatment throughout the study until PFS1 is documented by radiological disease progression', 'or the subject is lost to follow-up, death, withdraws study consent or starts a subsequent anti-', 'cancer therapy. Baseline imaging performed prior to informed consent as standard of care', '14 Sep 2020', 'Astellas', 'Page 44 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}